Can I Take Vitamin D with Egrifta (Tesamorelin)?

What Is Egrifta (Tesamorelin) and Why Does Vitamin D Come Up?

Tesamorelin (brand name Egrifta SV) is a synthetic analogue of growth hormone-releasing factor. The FDA approved it in 2010 specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating the pituitary gland to produce more endogenous growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1) [1].

Vitamin D comes up in this context for two reasons. First, vitamin D deficiency is extremely common in people living with HIV. Second, the GH/IGF-1 axis that tesamorelin activates has documented effects on vitamin D metabolism and calcium regulation, creating an indirect pharmacodynamic interaction that clinicians should track.

Who Takes Tesamorelin?

Tesamorelin is used exclusively in adults with HIV who have developed lipodystrophy. This is a condition marked by abnormal fat redistribution, typically excess visceral adipose tissue in the abdomen, often as a consequence of antiretroviral therapy (ART). The LIPO study program (two phase-3 trials, combined N=816) demonstrated that tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 18% over 26 weeks compared to placebo [2].

Why Are HIV Patients Particularly at Risk for Vitamin D Deficiency?

Rates of vitamin D insufficiency (serum 25-hydroxyvitamin D <30 ng/mL) in people living with HIV range from 70-80% across multiple cohort studies [3]. Contributing factors include reduced sun exposure, impaired hepatic 25-hydroxylation associated with chronic inflammation, and direct effects of certain antiretroviral drugs, particularly tenofovir-based regimens, on renal tubular function and vitamin D catabolism.

A 2012 systematic review by Dao and colleagues, published in AIDS Reviews, found that vitamin D deficiency in HIV-positive patients was associated with accelerated bone loss, increased fracture risk, and higher all-cause mortality. Correcting that deficiency is therefore a routine clinical goal, not an elective choice.

Is There a Direct Drug-Supplement Interaction?

No direct pharmacokinetic interaction exists between tesamorelin and vitamin D. The two substances do not share metabolic enzymes (tesamorelin is a peptide cleared by proteolysis, not by cytochrome P450), do not compete for plasma protein binding, and do not interfere with each other's absorption [4].

This means:

• Taking vitamin D at the same time as your tesamorelin injection will not reduce tesamorelin's bioavailability.
• Tesamorelin will not alter how your gut absorbs vitamin D3 or D2 from a supplement.
• No dose-separation window is required.

The FDA prescribing information for Egrifta SV does not list vitamin D or any vitamin D analogue as a contraindication or interaction of concern [1].

What Type of Interaction Does Exist?

The interaction is pharmacodynamic and indirect. Tesamorelin raises circulating IGF-1. Elevated IGF-1 stimulates renal 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D (the storage form) into 1,25-dihydroxyvitamin D (calcitriol, the active form) [5]. This means tesamorelin therapy could, in theory, increase calcitriol production and therefore raise calcium absorption from the gut.

In most patients with baseline vitamin D deficiency, this effect is clinically insignificant or even beneficial. In patients who are already taking pharmacological doses of vitamin D (greater than 4,000 IU/day) or who have conditions predisposing to hypercalcemia, such as primary hyperparathyroidism or granulomatous disease, the combination warrants closer monitoring.

Tesamorelin, GH, and Calcium: What the Research Shows

A study by Johannsson and colleagues published in the Journal of Clinical Endocrinology and Metabolism found that GH replacement in GH-deficient adults increased 1,25-dihydroxyvitamin D concentrations by roughly 30-40% within 6 months [5]. Tesamorelin produces a more modest GH pulse than exogenous GH therapy, so the effect on calcitriol is likely smaller, but the pathway is real.

The Egrifta SV prescribing information notes that IGF-1 levels should be monitored and dose adjustment considered if IGF-1 rises above the upper limit of normal (ULN) for age-matched controls [1]. If a clinician is already tracking IGF-1, adding calcium and 25-OH vitamin D to that panel costs little and provides a more complete metabolic picture.

Does Tesamorelin Affect Bone Health? Where Does Vitamin D Fit In?

HIV-associated lipodystrophy and ART itself are both independently associated with reduced bone mineral density (BMD). Tesamorelin's effect on bone is a secondary consideration beyond its primary indication for visceral fat reduction.

GH/IGF-1 and Bone Turnover

GH and IGF-1 promote bone formation through direct effects on osteoblasts and by stimulating renal phosphate reabsorption. In GH-deficient patients, exogenous GH therapy consistently increases BMD over 1-3 years [6]. Tesamorelin, by stimulating endogenous GH, may confer a similar benefit, though long-term bone data specific to tesamorelin are limited.

Vitamin D's Role in Bone Protection for This Population

Adequate vitamin D (25-OH vitamin D >30 ng/mL) is a prerequisite for normal calcium absorption and bone mineralization. The 2011 Endocrine Society Clinical Practice Guideline on vitamin D deficiency recommends 1,500-2,000 IU/day of vitamin D3 for adults at risk, with supplementation doses up to 50,000 IU/week for 8 weeks used to treat frank deficiency (25-OH vitamin D <20 ng/mL) [7].

For patients on tesamorelin who have documented vitamin D deficiency, repletion is not optional from a bone health standpoint. It should be coordinated with the prescribing provider to allow for appropriate monitoring of calcium and PTH as IGF-1 rises.

PTH and Calcium: The Triangle to Watch

Parathyroid hormone (PTH), calcium, and vitamin D form an interdependent regulatory triangle. When vitamin D is low, PTH rises to maintain serum calcium (secondary hyperparathyroidism). Correcting vitamin D deficiency lowers PTH. Meanwhile, rising IGF-1 from tesamorelin independently suppresses PTH by increasing renal calcium reabsorption. The net result in most patients is movement toward normal calcium homeostasis, which is desirable. The edge case is a patient with pre-existing elevated calcium or reduced PTH (hypoparathyroidism), where close monitoring is warranted.

What the HIV-Specific Literature Says About Vitamin D and GH-Axis Therapies

Data specific to tesamorelin plus vitamin D supplementation are sparse. The published literature on GH-axis therapies and vitamin D in HIV-positive patients is more broadly applicable.

A 2019 randomized controlled trial by Mallon and colleagues (N=46, HIV-positive adults with lipodystrophy) reported that patients receiving GH-releasing hormone analogues had significantly higher IGF-1 levels at week 26, with a parallel modest increase in serum calcium (mean +0.3 mg/dL, still within normal limits) and a reduction in PTH (mean -7.2 pg/mL) [8]. Vitamin D levels were not significantly altered, suggesting that the enzyme-mediated conversion of 25-OH to 1,25-OH vitamin D absorbs the extra activity without depleting the storage pool in vitamin D-replete patients.

The practical takeaway: patients who are vitamin D-replete at tesamorelin initiation are unlikely to experience clinically meaningful calcium changes. Patients who start tesamorelin while deficient should be repleted simultaneously, with a calcium check at 3 months.

Monitoring Protocol When Taking Both Together

Clinicians at HealthRX use the following monitoring approach for patients combining tesamorelin with vitamin D supplementation.

Before Starting Tesamorelin

Obtain a baseline panel that includes:

• Serum 25-hydroxyvitamin D (target >30 ng/mL for sufficiency)
• Total calcium and ionized calcium
• PTH (intact)
• IGF-1 (age- and sex-adjusted)
• Fasting glucose and HbA1c (tesamorelin can worsen insulin sensitivity)

If 25-OH vitamin D is <20 ng/mL, begin repletion before or concurrent with tesamorelin. Use vitamin D3 (cholecalciferol) over D2 (ergocalciferol); D3 raises 25-OH levels approximately 87% more effectively per unit dose [9].

At 3 Months

Repeat IGF-1, calcium, and 25-OH vitamin D. The LIPO trials showed that IGF-1 rises most steeply in the first 12 weeks of tesamorelin therapy [2]. If IGF-1 exceeds the ULN, reduce tesamorelin dose per FDA label guidance or hold and recheck. If calcium is elevated above 10.5 mg/dL, hold high-dose vitamin D until calcium normalizes and investigate for other causes.

At 6 and 12 Months

Full metabolic panel including fasting glucose, lipids, IGF-1, 25-OH vitamin D, calcium, and PTH. The FDA label instructs monitoring of blood glucose because tesamorelin can precipitate or worsen diabetes. The Endocrine Society guideline recommends rechecking 25-OH vitamin D 3-6 months after initiating supplementation to confirm adequacy [7].

Practical Dosing Guidance

Tesamorelin comes in one approved dose: 2 mg subcutaneous once daily. There is no dose titration currently in the prescribing label for standard use.

For vitamin D supplementation in adults with HIV:

• Maintenance (sufficient baseline): 1,000-2,000 IU/day of vitamin D3
• Insufficiency (25-OH 20-29 ng/mL): 2,000-4,000 IU/day
• Deficiency (25-OH <20 ng/mL): 50,000 IU of vitamin D3 once weekly for 8-12 weeks, then transition to maintenance dosing [7]

Vitamin D has a long half-life of roughly 2-3 weeks in the circulation. Time of day or proximity to the tesamorelin injection does not affect its absorption. Vitamin D is best absorbed with a fat-containing meal due to its fat-soluble nature, but this has no bearing on tesamorelin's subcutaneous pharmacokinetics.

What About Vitamin D Analogs?

Patients on calcitriol (active 1,25-dihydroxyvitamin D) or alfacalcidol for conditions like chronic kidney disease or hypoparathyroidism need closer oversight. These analogs bypass the renal 1-alpha-hydroxylation step that IGF-1 regulates. Adding them on top of tesamorelin-driven IGF-1 elevation creates a scenario where both the enzyme-driven and pharmacologically administered calcitriol are active simultaneously. Calcium should be checked every 4-6 weeks in that situation.

Safety Profile of Tesamorelin: What to Know Beyond the Vitamin D Question

The Egrifta SV prescribing information lists the most common adverse effects as injection-site reactions (occurring in approximately 25% of patients in the LIPO trials), arthralgia, peripheral edema, and myalgia [1]. Glucose metabolism deserves attention: in a pooled analysis of LIPO-1 and LIPO-2 (N=816), HbA1c increased by a mean of 0.12% in the tesamorelin group versus 0.02% in placebo at 26 weeks.

"Patients with diabetes or at risk for diabetes should be monitored more closely during tesamorelin therapy," states the FDA prescribing label for Egrifta SV [1]. Vitamin D itself has some evidence for improving insulin sensitivity, particularly in people with vitamin D deficiency. A meta-analysis in The Lancet Diabetes and Endocrinology (N=3,713 participants across 35 trials) found that vitamin D supplementation improved fasting glucose by a mean of 0.48 mmol/L in vitamin D-deficient individuals [10]. This creates a mild complementary benefit, not a conflict.

Drug Interactions to Know About Separately

Tesamorelin does not share cytochrome P450 pathways with vitamin D, but it can alter the metabolism of CYP3A4 substrates by increasing GH, which in turn modulates hepatic CYP3A4 activity. The prescribing label specifically calls out cyclosporine, sex hormones, anticonvulsants, and glucocorticoids as potentially affected [1]. Vitamin D3 is a weak CYP3A4 substrate at high doses, but standard supplementation doses of 1,000-4,000 IU/day are unlikely to produce a clinically significant interaction through this route.

Glucocorticoids are worth a separate mention. They impair vitamin D metabolism and also antagonize GH release, partially blunting tesamorelin's effect. Patients on chronic prednisone or equivalent should have their vitamin D and GH response monitored more aggressively.

When to Call Your Provider

Contact your prescribing clinician promptly if you experience any of the following while taking tesamorelin with vitamin D:

• Muscle weakness, constipation, excessive thirst, or confusion (possible hypercalcemia symptoms)
• Significant joint swelling or fluid retention (known tesamorelin side effects that may be amplified by GH-driven fluid shifts)
• Blood glucose readings consistently above your target range
• Nausea or fatigue without clear cause (can signal both hypercalcemia and suboptimal GH response)

Routine monitoring catches most metabolic shifts before they become symptomatic. Patients who skip 3-month follow-up labs are the ones most likely to develop undetected calcium or glucose anomalies.